Elicio Therapeutics (ELTX) Times Interest Earned (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Times Interest Earned came in at -$0.92 in Q1 2026, up 97.14% YoY from -$0.47 in Q1 2025, and up 96.49% on a QoQ basis from -$26.16 in Q4 2025.
Elicio Therapeutics (ELTX) Times Interest Earned (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Times Interest Earned data on file, last reported at -$0.92 in Q1 2026.
- Quarterly Times Interest Earned rose 97.14% year-over-year to -$0.92 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.25 (up 98.51% YoY) and the FY2025 annual result came in at -$7.46, down 1559.74% from the prior year.
- Times Interest Earned climbed to -$0.92 in Q1 2026, from -$26.16 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $21.02 in Q4 2024 to a low of -$75.5 in Q3 2024.
- A 5-year average of -$18.35 and a median of -$5.64 in 2022 frame the typical range for Times Interest Earned.
- The widest YoY moves for Times Interest Earned: up 184.61% in 2024, down 6342.8% in 2024.
- Tracing ELTX's Times Interest Earned over 5 years: stood at -$64.79 in 2022, then soared by 61.65% to -$24.85 in 2023, then surged by 184.61% to $21.02 in 2024, then slumped by 224.43% to -$26.16 in 2025, then jumped by 96.49% to -$0.92 in 2026.
- The last three Times Interest Earned figures came in at -$0.92 (Q1 2026), -$26.16 (Q4 2025), and -$0.76 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | -25.44 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.95 |
| Mar 31, 2026 | -0.92 |
| Dec 31, 2025 | -26.16 |
| Sep 30, 2025 | -0.76 |
| Jun 30, 2025 | -1.50 |
| Mar 31, 2025 | -32.14 |
| Dec 31, 2024 | 21.02 |
| Sep 30, 2024 | -75.50 |
| Jun 30, 2024 | -1.36 |
| Mar 31, 2024 | -27.02 |
| Dec 31, 2023 | -24.85 |
| Sep 30, 2023 | -1.17 |
| Jun 30, 2023 | -2.22 |
| Mar 31, 2023 | -22.82 |
| Dec 31, 2022 | -64.79 |
| Sep 30, 2022 | -1.29 |
| Jun 30, 2022 | -5.64 |
| Mar 31, 2022 | -44.85 |
| Dec 31, 2021 | 46.02 |
| Sep 30, 2021 | -0.62 |